Table 3.

Associations of bilirubin levels with cardiovascular outcomes among those on antiretroviral therapy stratified by atazanavir use and by hepatitis C virus co-infection status in adjusted analyses^*

	Hazard Ratio per 2-fold increase in bilirubin [95% confidence interval]
Outcome	HCV-uninfected and infected (combined)	Stratified by HCV status
		HCV-uninfected	HCV-infected
N (Limited to those on ART not including atazanavir)	20,305	16,706	3,599
Type 1 MI	0.70 [0.43, 1.15]	0.65 [0.36, 1.17]	0.82 [0.33, 2.04]
Type 2 MI	2.00 [1.52, 2.62]	2.11 [1.37, 3.25]	2.03 [1.40, 2.95]
Type I MI and ischemic stroke	0.91 [0.61, 1.35]	0.69 [0.41, 1.16]	1.29 [0.75, 2.22]
N (Limited to those on ART including atazanavir)	5,671
Type 1 MI	0.68 [0.43, 1.09]	**	**
Type 2 MI	0.56 [0.33, 1.00]
Type I MI and ischemic stroke	0.64 [0.41, 0.99]

HCV: hepatitis C virus

MI: myocardial infarction

^*Analyses adjusted for time-varying viral load and CD4 count, and baseline age, sex, race/ethnicity, HIV transmission risk factor, smoking status, hepatitis C virus status, diabetes, treated hypertension, statin use, kidney function (estimated GFR <30, 30–60, ≥60), calendar time, and site. Analyses stratified by HCV not adjusted for HCV.

^**Atazanavir analyses not stratified due to small outcome numbers

^***Note that ART use and atazanavir user are time-varying